Bulletin
Investor Alert

Syneos Health Inc. Cl A

NAS: SYNH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Feb 18, 2020, 5:01 p.m.

/zigman2/quotes/207981284/composite

$

66.51

Change

0.00 0.00%

Volume

Volume 46,963

Quotes are delayed by 20 min

/zigman2/quotes/207981284/composite

Previous close

$ 65.62

$ 66.51

Change

+0.89 +1.36%

Day low

Day high

$65.35

$66.63

Open

52 week low

52 week high

$36.72

$66.63

Open

Company Description

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning P...

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Morrisville, NC.

Valuation

P/E Current

282.92

P/E Ratio (with extraordinary items)

80.25

P/E Ratio (without extraordinary items)

169.69

Price to Sales Ratio

0.94

Price to Book Ratio

1.42

Price to Cash Flow Ratio

13.72

Enterprise Value to EBITDA

16.45

Enterprise Value to Sales

1.96

Total Debt to Enterprise Value

0.42

Efficiency

Revenue/Employee

182,922.00

Income Per Employee

1,012.00

Receivables Turnover

3.86

Total Asset Turnover

0.60

Liquidity

Current Ratio

0.99

Quick Ratio

0.99

Cash Ratio

0.10

Profitability

Gross Margin

15.54

Operating Margin

6.28

Pretax Margin

1.30

Net Margin

0.55

Return on Assets

0.33

Return on Equity

0.83

Return on Total Capital

4.71

Return on Invested Capital

0.42

Capital Structure

Total Debt to Total Equity

99.00

Total Debt to Total Capital

49.75

Total Debt to Total Assets

38.98

Long-Term Debt to Equity

96.77

Long-Term Debt to Total Capital

48.63

Officers and Executives

Name Age Officer Since Title
Mr. Alistair John Macdonald 49 2010 Executive Vice President-Strategic Development
Mr. Jason Michael Meggs 43 2018 Chief Financial Officer & Executive Vice President
Ms. Michelle Keefe - - President-Commercial Solutions
Mr. Paul D. Colvin 49 2019 President-Clinical Solutions
Mr. Neil Ferguson - - Chief Business Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/27/2020 Alistair John Macdonald
Chief Executive Officer; Director
13,545   Derivative/Non-derivative trans. at $62.69 per share. 849,136
01/27/2020 Jason Michael Meggs
Chief Financial Officer
380   Derivative/Non-derivative trans. at $62.69 per share. 23,822
01/19/2020 Alistair John Macdonald
Chief Executive Officer; Director
1,293   Derivative/Non-derivative trans. at $63.83 per share. 82,532
01/19/2020 Jason Michael Meggs
Chief Financial Officer
129   Derivative/Non-derivative trans. at $63.83 per share. 8,234
01/17/2020 Robert Alan Parks
EVP, Chief Accounting Officer
4,135   Award at $0 per share. 0
01/15/2020 Alistair John Macdonald
Chief Executive Officer; Director
48,770   Award at $0 per share. 0
01/15/2020 Jason Michael Meggs
Chief Financial Officer
13,803   Award at $0 per share. 0
01/15/2020 Michelle Keefe
Pres., Commercial Solutions
11,862   Award at $0 per share. 0
01/15/2020 Jonathan Olefson
General Counsel & Corp Secty
6,692   Award at $0 per share. 0
01/15/2020 Paul D. Colvin
Pres., Clinical Solutions
11,862   Award at $0 per share. 0
01/08/2020 Alistair John Macdonald
Chief Executive Officer; Director
10,155   Derivative/Non-derivative trans. at $59.96 per share. 608,893
01/08/2020 Jason Michael Meggs
Chief Financial Officer
1,732   Derivative/Non-derivative trans. at $59.96 per share. 103,850
01/08/2020 Michelle Keefe
Pres., Commercial Solutions
1,559   Derivative/Non-derivative trans. at $59.96 per share. 93,477
01/08/2020 Jonathan Olefson
General Counsel & Corp Secty
1,095   Derivative/Non-derivative trans. at $59.96 per share. 65,656
01/08/2020 Paul D. Colvin
Pres., Clinical Solutions
1,404   Derivative/Non-derivative trans. at $59.96 per share. 84,183
01/08/2020 Robert Alan Parks
EVP, Chief Accounting Officer
679   Derivative/Non-derivative trans. at $59.96 per share. 40,712
01/02/2020 Paul D. Colvin
Pres., Clinical Solutions
249   Derivative/Non-derivative trans. at $59.51 per share. 14,817
12/03/2019 Robert Alan Parks
EVP, Chief Accounting Officer
660   Derivative/Non-derivative trans. at $54.4 per share. 35,904
12/01/2019 Michelle Keefe
Pres., Commercial Solutions
364   Derivative/Non-derivative trans. at $54.89 per share. 19,979
11/13/2019 Jonathan Olefson
General Counsel & Corp Secty
1,047   Derivative/Non-derivative trans. at $49.47 per share. 51,795
11/12/2019 Bernadette M. Connaughton
Director
1,909   Award at $49.48 per share. 94,457
/news/latest/company/us/synh

MarketWatch News on SYNH

  1. 30 momentum stocks that are actually cheap enough to buy

    2:23 p.m. Dec. 12, 2019

    - Michael Brush

  2. Syneos Health stock price target raised to $57 vs.s $53.50 at UBS, 'overhang removed' after SEC probe

    9:29 a.m. Aug. 29, 2019

    - Ciara Linnane

  3. Syneos Health downgraded to neutral from buy at UBS

    9:12 a.m. March 20, 2019

    - Tomi Kilgore

  4. Syneos Health started at buy with $60 stock price target at UBS

    2:14 p.m. Oct. 9, 2018

    - Tomi Kilgore

  5. Elliott Associates Thinks It Can Make Nielsen Click

    2:14 p.m. Aug. 20, 2018

    - Barron's Online

  6. Here are Wall Street’s 19 favorite mid-cap stocks for 2018

    7:30 a.m. Dec. 8, 2017

    - Philip van Doorn

  7. Healthcare Stocks: Calm After The Storm?

    10:16 a.m. Aug. 1, 2017

    - Barrons Blogs

  8. INC Research stock price target raised to $67 from $51 at Raymond James

    7:23 a.m. June 8, 2017

    - Tomi Kilgore

  9. INC Research upgraded to overweight from sector weight at KeyBanc Capital

    6:25 a.m. June 5, 2017

    - Tomi Kilgore

  10. INC Research stock price target raised to $67 vs. $48 at SunTrust Robinson Humphrey

    6:31 a.m. May 31, 2017

    - Ciara Linnane

  11. INC Research upgraded to buy at SunTrust Robinson Humphrey

    6:30 a.m. May 31, 2017

    - Ciara Linnane

  12. Starboard Value Sees Possible Sale of Parexel

    12:23 a.m. May 20, 2017

    - Barron's Online

  13. INC Research upgraded to outperform from neutral at RW Baird

    6:29 a.m. May 11, 2017

    - Tomi Kilgore

  14. Stock winners and losers — Nvidia rockets and Yelp tumbles

    10:33 a.m. May 10, 2017

    - Philip van Doorn

  15. Pain may be in store for the S&P 500, says Goldman

    7:32 a.m. Sept. 13, 2016

    - Ryan Vlastelica

  16. Loading more headlines...
/news/nonmarketwatch/company/us/synh

Other News on SYNH

  1. IPO Update: PPD Readies $1.5 Billion U.S. IPO

    2:51 p.m. Jan. 28, 2020

    - Seeking Alpha

  2. Stocks To Watch: Bright Lights On Healthcare And Retail

    7:28 a.m. Jan. 11, 2020

    - Seeking Alpha

  3. PPD Begins U.S. IPO Plan Rollout

    4:38 p.m. Jan. 9, 2020

    - Seeking Alpha

  4. 5 Best Value Picks to Grab on Discounted PEG

    8:01 a.m. Jan. 8, 2020

    - Zacks.com

  5. Sell-siders update coverage ahead of JPM20 - Initiations

    7:23 a.m. Jan. 7, 2020

    - Seeking Alpha

  6. Is Syneos Health (SYNH) a Great Value Stock Right Now?

    9:10 a.m. Nov. 20, 2019

    - Zacks.com

  7. Syneos Health (SYNH) Surpasses Q3 Earnings Estimates

    6:35 a.m. Oct. 31, 2019

    - Zacks.com

  8. 10-Q: SYNEOS HEALTH, INC.

    5:33 a.m. Oct. 31, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  9. Loading more headlines...

At a Glance

Syneos Health, Inc.

1030 Sync Street

Morrisville, North Carolina 27560-5468

Phone

1 9198769300

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2019

Revenue

$4.39B

Net Income

$24.28M

2018 Sales Growth

64.3%

Employees

24,000

/news/pressrelease/company/us/synh

Press Releases on SYNH

  1. Clinical Trials Services Market looks to expand its size in Overseas Market

    2:57 a.m. Dec. 28, 2019

    - HTF Market Intelligence

  2. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.